Get an email when this journal's indexing changes
Added to or removed from Scopus, Web of Science, ABDC, DOAJ, FT50, UT Dallas or ONOS. One confirmation click; unsubscribe anytime.
Bladder Cancer is Scopus-indexed (Q3, CiteScore 2.1), WoS SCIE, DOAJ. Published by SAGE Publications Ltd.
Checked against the index lists dated .
ISSN 2352-3727Verify ISSN ↗2352-3735Verify ISSN ↗
Publisher: SAGE Publications Ltd
Cost to publish: Checking DOAJ for article charges…
| Subject area | Rank | Pctile | Q |
|---|---|---|---|
| Urology | 70 / 123 | 43rd | Q3 |
| Oncology | 291 / 428 | 32nd | Q3 |
Not listed in: ABDC, ABS / AJG, FT50, UT Dallas, ONOS (subscription), ONOS (APC covered)
Yes — actively indexed in Scopus, coverage 2015–present, best quartile Q3, CiteScore 2.1.
Bladder Cancer is Q3 in Urology (rank 70 of 123) and Q3 in Oncology (rank 291 of 428), by CiteScore 2025.
Bladder Cancer is indexed in the Science Citation Index Expanded, so it may have a Journal Impact Factor in Clarivate's Journal Citation Reports. JCR is paid, so check it for the current value. The closest free measure is its Scopus CiteScore 2.1, which places it in quartile Q3 at the 43rd percentile of its subject. Its SCImago Journal Rank (SJR, a free Scopus-based metric) is 0.595, quartile Q2, with an H-index of 33.
Bladder Cancer is published by SAGE Publications Ltd. Its print ISSN is 2352-3727 and its online ISSN is 2352-3735.
Yes — indexed in the Science Citation Index Expanded.
Yes — it is an open-access journal, listed in DOAJ.
Bladder Cancer has an h-index of 37 and a 2-year mean of 2.27 citations per paper (OpenAlex). Its Scopus CiteScore is 2.1, quartile Q3. On 2-year citations it ranks #29 of 123 Scopus journals in Urology.
Bladder Cancer published 28 papers in 2025; its busiest recent year was 2021 with 99. 2026* is the year so far.
h-index, i10-index and 2-year mean citedness are open, licence-clear metrics from OpenAlex — not a proprietary impact factor. The subject rank counts only journals that OpenAlex has a figure for; it is not a Scopus or Clarivate ranking. Updated 2026-10-14.
In its latest 100 research articles (2023–2026), authors are most often from United States (61%), United Kingdom (4.6%) and Japan (3.4%). More than half of recent authorship comes from one country.
Countries are counted fractionally, so a paper by authors from two countries counts half to each.
Scopus status: Active. No retracted papers are recorded. The Problematic Paper Screener flags none of its papers. These are indicators to check, not findings against the journal.
Retractions from OpenAlex; flags from the Problematic Paper Screener (Cabanac, Labbé & Magazinov, CC BY), 2026-09-21 export. A flag marks a paper for a closer look; it is not a finding against the journal.
Index data is curated from public sources (Scopus, Web of Science, ABDC, FT50, UT Dallas, DOAJ). CiteScore and quartiles reflect the latest available Scopus release. Always verify a journal's current status on its official source before submitting.
Comments load as you scroll here.